Piperacillin-Tazobactam in HIV-Associated Bacterial Pneumonia

Indications and Treatment Regimens

The Centers for Disease Control and Prevention recommends piperacillin-tazobactam for HIV patients with bacterial pneumonia when there are risk factors for Pseudomonas aeruginosa infection, particularly in those requiring intensive care 1
Piperacillin-tazobactam is indicated for HIV patients with risk factors for Pseudomonas infection, including advanced HIV disease, pre-existing lung disease, underlying neutropenia, corticosteroid therapy, or severe malnutrition 1, 2
The recommended regimen for severe pneumonia requiring ICU care is combination therapy with piperacillin-tazobactam and either ciprofloxacin or levofloxacin, or an aminoglycoside and azithromycin 1
For outpatient treatment, oral beta-lactam plus oral macrolide is recommended, but piperacillin-tazobactam is not indicated 3
For non-ICU inpatient treatment, IV beta-lactam plus macrolide is recommended, but piperacillin-tazobactam could be used but is not specifically mentioned as preferred 4

The Centers for Disease Control and Prevention recommends avoiding fluoroquinolone monotherapy in HIV patients when TB is suspected, as it may mask TB and delay appropriate multi-drug TB therapy 3
The Centers for Disease Control and Prevention recommends never using macrolide monotherapy for bacterial pneumonia in HIV patients due to increased risk of drug-resistant Streptococcus pneumoniae 3
Annual influenza vaccination is recommended for all HIV-infected persons 3
Pneumococcal vaccination is recommended for HIV-infected patients 4

The Centers for Disease Control and Prevention recommends piperacillin-tazobactam for HIV patients with pneumonia when there are risk factors for Pseudomonas aeruginosa infection, with a dosage of 4.5 g (4 g piperacillin and 0.5 g tazobactam) administered intravenously every 6 hours 5
Piperacillin-tazobactam is one of the preferred beta-lactams for empiric Pseudomonas coverage in pneumonia requiring hospitalization, according to the Centers for Disease Control and Prevention 5, 6

HIV patients have an increased risk of drug-resistant Streptococcus pneumoniae, requiring careful antibiotic selection, as stated by the Centers for Disease Control and Prevention 7, 8
The Centers for Disease Control and Prevention advises against using macrolide monotherapy for bacterial pneumonia in HIV patients due to increased risk of drug-resistant pathogens 7, 8
The Centers for Disease Control and Prevention recommends avoiding fluoroquinolone monotherapy when tuberculosis is suspected, as it may mask TB and delay appropriate multi-drug TB therapy 7, 8

For non-ICU inpatients with risk factors for Pseudomonas, the Infectious Diseases Society of America recommends piperacillin-tazobactam 4.5 g IV every 6 hours 9, 6
For patients with hospital-acquired pneumonia who are at high risk of mortality, the Infectious Diseases Society of America recommends piperacillin-tazobactam 4.5 g IV every 6 hours 9